home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Inhibiting Lymphatic Vessel Growth

  August, 13 2009 15:16
your information resource in human molecular genetics

The discovery of the first endogenous inhibitor of lymphatic vessel growth is reported in Nature Medicine. The finding could potentially lead to treatment in cases of transplantation rejection and lymph vessel growth in tumours.

The lymphatic system is crucial in transporting fluids and molecules to cells as well as draining unwanted fluids. The disruption of the balance between positive and negative regulators for blood and lymphatic vessel growth can lead to many diseases. Although many natural inhibitors of blood vessel growth exist, an endogenous selective inhibitor of lymphatic vessel growth - lymphangiogenesis - had previously not been described.

Jayakrishna Ambati and his colleagues report the existence of such an inhibitor, called soluble Vegfr-2. Soluble Vegfr-2 inhibits lymphangiogenesis by blocking signaling of the protein Vegf-c. In mice, tissue-specific loss of soluble Vegfr-2 induced spontaneous growth of lymphatic system to structures that normally lack lymphatic vessels, such as the cornea. Administration of soluble Vegfr-2 after injury or transplantation also inhibited lymphangiogenesis but not blood vessel growth, and therefore enhanced mice's survival after graft surgery.

Owing to the selective effects of soluble Vegfr-2 on lymphatic vessels while sparing blood vessels, it might lead to potential treatments for lymphatic vascular malformations, transplantation rejection and tumor lymphangiogenesis.

Author contact:

Jayakrishna Ambati (University of Kentucky, Lexington, KY, USA)
E-mail: jamba2@email.uky.edu

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.